A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load
Clinical Infectious Diseases (2021) - Comments
pubmed: 34718468  doi: 10.1093/cid/ciab912  issn: 1058-4838  issn: 1537-6591 

Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L Gottlieb, Peter Chen, Corey Hebert, Russell Perry, Joseph Boscia, Barry Heller, Jason Morris, Chad Crystal, Awawu Igbinadolor, Gregory Huhn, Jose Cardona, Imad Shawa, Princy Kumar, Andra Blomkalns, Andrew C Adams, Jacob Van Naarden, Kenneth L Custer